Claybrook Capital’s Zimmer Biomet ZBH Stock Holding History

Claybrook Capital’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,360	Closed	-$212K	–	260
2021 Q2	$212K	Buy	+1,360	New	+$220K	0.07%	159
2018 Q4	–	Sell	-41	Closed	-$5K	–	833
2018 Q3	$5K	Hold	41	–	–	﹤0.01%	171
2018 Q2	$4K	Hold	41	–	–	﹤0.01%	174
2018 Q1	$4K	Buy	+41	New	+$4.76K	﹤0.01%	173

Other funds holding ZBH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Claybrook Capital's ZBH Position: Q3 2021 in Review

Claybrook Capital sold out of Zimmer Biomet (ZBH) in Q3 2021, closing a stake of 1,360 shares — an estimated $212K sold.

Claybrook Capital first reported a position in ZBH in Q1 2018 and held it in 4 quarters. The position peaked at $212K in Q2 2021. 982 funds tracked by Wall St. Rank hold ZBH as of Q3 2021.

Claybrook Capital reported no remaining Zimmer Biomet position as of Q3 2021 after selling out during the quarter.
Claybrook Capital sold 1,360 Zimmer Biomet shares in Q3 2021, an estimated $212K.
Claybrook Capital first reported a position in Zimmer Biomet in Q1 2018 and held it in 4 quarters.
Claybrook Capital's Zimmer Biomet position peaked at $212K in Q2 2021.
982 funds tracked by Wall St. Rank held Zimmer Biomet as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.